


Technical Report No. 29 (Revised 2012)

Points to Consider for Cleaning Validation

PCMO
Paradigm Change in
Manufacturing OperationsSM



2012



**PDA Task Force on Technical Report No. 29 (Revised 2012):
Points to Consider for Cleaning Validation**

Authors

Destin A. LeBlanc, Cleaning Validation Technologies
(Chair)

Gretchen Allison, Pfizer

Jennifer L. Carlson, Genentech

Koshy George, Consultant

Igor Gorsky, ConcordiaValSource

Irwin S. Hirsh, Novo Nordisk AS

Jamie Osborne, Siegfried (USA), Inc.

Greg Randall, Baxter Bioscience

Pierre-Michel Riss, Eli Lilly

George Verghese, STERIS Corporation

Jenn Walsh, Bristol-Myers Squibb

Vivienne Yankah, Sanofi-Pasteur, Ltd.

The content and views expressed in this Technical Report are the result of a consensus achieved by the authorizing Task Force and are not necessarily views of the organizations they represent.

Points to Consider for Cleaning Validation

Technical Report No. 29 (Revised 2012)

ISPN: 8-0-939459-48-3

© 2012 Parenteral Drug Association, Inc.

All rights reserved.



Paradigm Change in Manufacturing Operations (PCMOSM)

PDA launched the project activities related to the PCMO program in December 2008 to help implement the scientific application of the ICH Q8, Q9 and Q10 series. The PDA Board of Directors approved this program in cooperation with the Regulatory Affairs and Quality Advisory Board, and the Biotechnology Advisory Board and Science Advisory Board of PDA.

Although there are a number of acceptable pathways to address this concept, the PCMO program follows and covers the drug product lifecycle, employing the strategic theme of process robustness within the framework of the manufacturing operations. This project focuses on Pharmaceutical Quality Systems as an enabler of Quality Risk Management and Knowledge Management.


Using the Parenteral Drug Association's (PDA) membership expertise, the goal of the Paradigm Change in Manufacturing Operations Project is to drive the establishment of 'best practice' documents and /or training events in order to assist pharmaceutical manufacturers of Investigational Medicinal Products (IMPs) and commercial products in implementing the ICH guidelines on Pharmaceutical Development (ICH Q8, Q11), Quality Risk Management (ICH Q9) and Pharmaceutical Quality Systems (ICH Q10).

The PCMO program facilitates communication among the experts from industry, university and regulators as well as experts from the respective ICH Expert Working Groups and Implementation Working Group. PCMO task force members also contribute to PDA conferences and workshops on the subject.

PCMO follows the product lifecycle concept and has the following strategic intent:

- Enable an innovative environment for continual improvement of products and systems
- Integrate science and technology into manufacturing practice
- Enhance manufacturing process robustness, risk-based decision making and knowledge management
- Foster communication among industry and regulatory authorities

The Product Life Cycle



For more information, including the PCMO Dossier, and to get involved, go to www.pda.org/pcmo

Table of Contents

1.0 Introduction	1		
1.1 Purpose/Scope	1		
2.0 Glossary of Terms	3		
2.1 Definition of Acronyms	5		
3.0 Cleaning Process Design and Development	7		
3.1 Cleaning Process Design	7		
3.2 Cleaning Process Overview	8		
3.2.1 Physical-chemical Aspects	9		
3.3 Design Considerations.....	10		
3.3.1 Location of Cleaning	10		
3.3.1.1 In-Place Cleaning.....	10		
3.3.1.1.1 Clean-in-Place (CIP) Systems	10		
3.3.1.1.2 Solvent Reflux Cleaning.....	11		
3.3.1.1.3 Placebo Batches as a Cleaning Method	11		
3.3.1.2 Out-of-Place Cleaning.....	11		
3.3.1.2.1 Clean-Out-of-Place Systems.....	12		
3.3.2 Automated vs. Manual Systems	12		
3.3.2.1 Manual Processes	12		
3.3.2.2 Semi-Automated Processes	12		
3.3.2.3 Automated Processes	13		
3.3.3 Soil Evaluation and Categorization.....	13		
3.3.3.1 Soil Categories	13		
3.3.3.2 Soil Removal.....	13		
3.3.4 Equipment Considerations.....	14		
3.3.4.1 Dedicated – Nondedicated Manufacturing Equipment	14		
3.3.4.2 Nonproduct Contact – Product Contact Surfaces	15		
3.3.4.3 Low-Risk Sites – High-Risk Sites ..	15		
3.3.4.4 Materials of Construction	15		
3.3.5 Operational Considerations.....	15		
3.3.6 Cleaning Agent Selection	16		
3.3.7 Product Considerations.....	16		
3.3.7.1 Product Risk Considerations.....	17		
3.4 Cleaning Development			
Laboratory Experiments	17		
3.4.1 Soil Selection	17		
3.4.2 Parameter Selection	18		
3.4.2.1 Parameter Interactions	19		
3.4.3 Measurements to Determine Cleaning Effectiveness	19		
3.5 Cleaning Process Scale-Up.....	19		
3.5.1 Setting Process Controls	19		
3.6 Applying the “Design Space” Concept to Cleaning Processes	20		
3.7 Standard Operating Procedures.....	21		
3.8 Operator Training for the Cleaning Process.....	21		
3.9 Introduction of New Products to a Validated Cleaning System	22		
4.0 Qualification	23		
4.1 Protocol Elements.....	23		
4.2 Key Protocol Issues	23		
4.2.1 Number of Runs in a Protocol	24		
4.2.2 Mock Soiling	24		
4.2.3 Worst-Case Process Conditions	24		
4.2.4 Disposition of Products and Equipment during Validation	25		
4.3 Grouping/Family Approach	25		
4.3.1 Product Grouping.....	26		
4.3.2 Equipment Grouping	26		
4.3.3 Introduction of a New Product or Equipment into a Group	27		
4.4 “Cleaning Verification” Documentation	27		
5.0 Residue and Limits	29		
5.1 Considerations for Developing Limits	29		
5.2 The Basis for Quantitative Limits	30		
5.3 Acceptable Concentration of Residue in Next Product	30		
5.3.1 ARL Based on Drug Active Dose	30		
5.3.2 ARL Based on Toxicity.....	31		
5.3.2.1 ADE Determinations Based on ISPE’s Risk-MaPP.....	31		
5.3.2.2 Toxicity Calculations Based on LD ₅₀ Data	32		
5.3.3 Other ARL Determinations	33		
5.4 Acceptable Total Carryover	33		
5.5 Surface Area Limit.....	34		
5.6 Limit in Protocol Samples.....	34		
5.6.1 Limit per Swab	34		
5.6.2 Concentration Limit in Extracted Swab Solvent	34		
5.6.3 Concentration Limit in Rinse Sampling Solution.....	35		
5.7 Consolidated Expressions.....	35		
5.8 Example Calculations	36		
5.9 Other Considerations	36		
5.9.1 Multiple Next Products.....	36		
5.9.2 Next Product in Verification Approach.....	37		
5.9.3 Default Limits	37		

5.9.4	Use of Different Safety Factors.....	38	6.6.1	Key Issues for Training for Swab Sampling	52
5.9.5	Different Routes of Administration.....	38	6.6.2	Key Issues for Training for Rinse Sampling	52
5.9.6	Different Doses for Adults and Children	38	6.6.3	Training for Visual Inspection.....	52
5.9.7	Human and Veterinary Products Manufactured on the Same Equipment	38	7.0 Analytical Methods	54	
5.9.8	Residues of Genotoxic and Other Highly Hazardous Active Ingredients	38	7.1	Purposes of the Analytical Methods.....	54
5.9.9	Limits Based on Analytical Detection Limits	39	7.2	Practical Considerations in Selecting Analytical Methods.....	54
5.9.10	Degradation of the Active Ingredient	39	7.3	Specific vs. Nonspecific Analytical Methods for Validation Protocols.....	55
5.9.11	Limits Not Measureable	39	7.3.1	Regulatory Status of Specific and Nonspecific Methods	55
5.9.12	Limits for Organic Solvents.....	39	7.4	Most Commonly Used Analytical Techniques	56
5.9.13	Dedicated Equipment	40	7.4.1	Liquid Chromatography (LC)	56
5.9.14	Dividing a Limit among Various Pieces of Equipment	40	7.4.2	Ultra Violet, Visible Spectrophotometry (UV/Vis)	57
5.9.15	Limits for Preferential Transfer to a First Portion of the Next Product	40	7.4.3	Total Organic Carbon (TOC)	57
5.9.16	Limits for Biotechnology Manufacture.....	40	7.4.4	Conductivity	57
5.9.17	Products with More Than One Active Ingredient	41	7.4.5	Organoleptic Evaluation	58
5.10	Bioburden Limits.....	41	7.5	Other Useful Analytical Techniques	59
5.11	Endotoxin Limits	42	7.5.1	pH.....	59
5.12	Visually Clean Criterion	42	7.5.2	InfraRed (IR)	59
6.0 Sampling.....	43		7.5.3	Light Microscopy.....	59
6.1	Sampling Method Selection	43	7.5.4	Titrations	59
6.1.1	Direct Sampling Methods	43	7.5.5	Gravimetric Analysis	59
6.1.1.1	Visual Inspection	43	7.5.6	Enzyme Linked Immunosorbant Assay (ELISA)	60
6.1.1.2	Instrumental Methods	44	7.5.7	Capillary Zone Electrophoresis (CZE)	60
6.1.2	Rinse Sampling	44	7.5.8	Atomic Absorption (AA) and Inductively Coupled Plasma (ICP)	60
6.1.2.1	Extraction Rinse Sampling for Small Parts.....	46	7.5.9	Ion Mobility Spectrometry (IMS)	60
6.1.2.2	Solvent Rinse Sampling.....	46	7.6	Microbial Test Methods.....	60
6.1.3	Swab and Wipe Sampling	46	7.6.1	Endotoxin	60
6.2	Placebo Sampling.....	47	7.6.2	Bioburden.....	60
6.3	Sampling for Microbial and Endotoxin Analysis.....	47	7.7	Analytical Method Validation.....	61
6.4	Additional Considerations.....	48	7.7.1	General Principles.....	61
6.5	Sampling Recovery Studies.....	48	7.7.2	Compendial Methods.....	62
6.5.1	General Considerations.....	48	7.7.3	Visual Inspection	63
6.5.2	Swab/Wipe Recovery.....	49	7.7.4	Bioburden Methods	63
6.5.3	Rinse Recovery.....	50	7.7.5	Transfer to another Laboratory and Use of Contract Laboratories	63
6.5.4	"Recovery" in Visual Inspection	51	8.0 Maintenance of Validated State.....	64	
6.5.5	Recovery for Bioburden and Endotoxin Sampling.....	51	8.1	Critical Parameter Measurement	64
6.6	Training and Qualification of Samplers.....	51	8.2	Process Alarms	64
			8.3	Change Control.....	65

8.4 Routine Monitoring.....	66	10.5.1.3 Grouping Impact.....	81
8.5 Data Trending and Review.....	66	10.5.1.4 Limit Calculation Impact.....	81
8.6 Evaluation of Cumulative Changes.....	67	10.5.2 Used Equipment.....	81
8.7 Training.....	67	10.6 Measurement Systems Analysis (MSA).....	81
8.8 Periodic Review.....	67	10.6.1 MSA Components.....	82
9.0 Documentation.....	69	10.6.2 Attribute R&R.....	82
9.1 Cleaning Validation Master Plans.....	69	10.6.3 Minimizing Variations.....	82
9.1.1 Elements of a Comprehensive Plan....	70	10.6.4 MSA and Cleaning Validation Strategy.....	82
9.1.2 Harmonization of Site Cleaning Validation Programs.....	71	10.7 Cleaning for API Manufacture.....	83
9.2 Documentation for Design/Development.....	71	10.8 Topical Drug Products.....	84
9.3 Documentation for Qualification.....	72	10.8.1 Topical Drug Products with Systemic Availability.....	84
9.4 Documentation for Validation Maintenance...	72	10.8.2 Topical Drug Products with No or Limited Systemic Availability.....	85
9.5 Other Documentation Considerations.....	73	10.8.2.1 Adjusted Calculation.....	85
10.0 Special Considerations.....	75	10.8.2.2 Modification Based on Frequency of Application.....	85
10.1 Cleaning Agents.....	75	10.8.2.3 Modification Based on Amount Applied per Surface Area.....	85
10.1.1 Types.....	75	10.8.2.4 Additional Considerations.....	86
10.1.1.1 Water.....	75	10.8.3 Additional Safety Considerations.....	86
10.1.1.2 Organic Solvents.....	75	10.8.4 Additional Cleaning Considerations...	86
10.1.1.3 Commodity Alkali.....	75	10.9 Animal Drug Products.....	86
10.1.1.4 Commodity Acids.....	75	10.10 Packaging Components and Packaging Equipment.....	86
10.1.1.5 Formulated Detergents.....	75	10.10.1 Primary Packaging Components.....	86
10.1.2 Factors in Selection.....	76	10.10.1.1 Oral Dosage Forms Primary Packaging Components.....	87
10.1.2.1 Broad Spectrum Effectiveness.....	76	10.10.1.2 Parenteral Dosage Forms Primary Packaging Components.....	87
10.1.2.2 Substrate Compatibility.....	76	10.10.2 Packaging Equipment.....	87
10.1.2.3 Stability and Shelf Life.....	76	10.10.2.1 Primary Packaging Equipment.....	87
10.1.2.4 Analyzability.....	76	10.10.2.2 Secondary Packaging Equipment.....	88
10.1.2.5 Disposal.....	76	10.11 Tubing and Hoses.....	88
10.1.2.6 Safety.....	76	10.12 Excipients.....	89
10.1.2.7 Toxicity.....	76	10.13 Dedicated Equipment.....	89
10.1.2.8 Rinsability.....	76	10.13.1 Reasons for Dedication.....	89
10.1.2.9 Quality.....	76	10.13.2 Cleaning Validation Issues.....	90
10.2 Nonproduct Contact Surfaces.....	76	11.0 Regulatory and Guidance Documents.....	91
10.3 Process Analytical Technology.....	77	12.0 References.....	92
10.3.1 Timely Measurements.....	77	13.0 Suggested Readings.....	94
10.3.2 PAT for Cleaning Process Control.....	77		
10.3.3 Additional Considerations for Online Measurements.....	78		
10.4 Clean Hold Considerations.....	78		
10.5 New and Used Equipment.....	80		
10.5.1 New Equipment.....	80		
10.5.1.1 Cleaning Procedure Development...	80		
10.5.1.2 Post-Installation Cleaning.....	81		

FIGURES AND TABLES INDEX

Table 3.1-1	CPP and CQA Considerations that have Potential Risk Impact to a Cleaning Process 7	Table 6.1.2-2	Advantages and Limitations of Rinse Sampling..... 45
Table 3.1-2	The Cleaning Spectrum 8	Table 6.1.3-1	Advantages and Limitations of Swab/Wipe Sampling..... 47
Table 3.2-1	Cleaning Process Steps (Examples) 9	Figure 9.5-1	Documentation for Process Flow..... 7
Table 6.1.2-1	Comparison of Grab Sampling versus Separate Sampling Rinse..... 45		

Currently in preview, click buy full version

1.0 Introduction

Cleaning validation plays an important role in reducing the possibility of product contamination from pharmaceutical manufacturing equipment. It demonstrates that the cleaning process adequately and consistently removes product residues, process residues and environmental contaminants from the manufacturing equipment/system, so that this equipment/system can be safely used for the manufacture of specified subsequent products (which may be the same or a different product). As used in this Technical Report, “product” may be a drug product, active pharmaceutical ingredient, intermediate, or another type of formulation. If “drug product” is intended, that terminology will be utilized. Principles and practices given in this report may apply to a variety of manufacturing situations. It is incumbent on the reader to decide the appropriateness of those principles and practices to his/her specific situation.

This report builds on the 1998 *PDA Technical Report No. 29, Points to Consider for Cleaning Validation (1)*. This report also has utilized principles and specific wording from the 2010 *PDA Technical Report No. 49, Points to Consider for Biotechnology Cleaning Validation (2)*. The authors of this revised Technical Report #29 would like to thank the members of the Task Forces who were responsible for the two earlier documents for making our job easier.

This revised Technical Report presents updated information that is aligned with lifecycle approaches to validation and the International Conference on Harmonisation (ICH) guidelines Q8 (R2) - *Pharmaceutical Development*, Q9 - *Quality Risk Management* and Q10 - *Pharmaceutical Quality System (3,4,5)*. Also, this report aims to assist readers who want to create or benchmark a cleaning validation program for their equipment and facilities.

This Task Force was composed of European and North American professionals from pharmaceutical manufacturers, cleaning chemical suppliers, and consulting companies. The report has undergone a global, technical peer review to ensure concepts, terminology, and practices presented are reflective of sound science and can be used globally.

1.1 Purpose/Scope

This Technical Report covers all facets of cleaning validation for pharmaceutical manufacturers, including both manufacturers of APIs and drug products. It also applies to biotechnology manufacturing; however, the reader should consult *PDA Technical Report No. 49, Points to Consider for Biotechnology Cleaning Validation* for more detail and specifics for biotechnology manufacturing (2). We have included a lifecycle cleaning validation approach, including design/development of the cleaning process, process qualification (including the protocol runs), and ongoing validation maintenance. While the document discusses risk-based approaches, it does not provide details about risk-based manufacturing. PDA has formed a Task Force to write a Technical Report on that topic.

We cannot emphasize enough how important risk analyses are in the selection of and validation of cleaning processes and their validation. This includes the traditional risk analysis based on effects on product quality and on patients. It also includes business risk considerations, such as steps taken to minimize lost product from contamination (even if detection systems are in place to prevent release of that contaminated product for consumer use).

These practices and the associated guidance in this Technical Report are based on technical considerations and should be applicable in all regulatory environments. However, the intent of this Technical Report is not to provide a detailed plan or roadmap for a pharmaceutical manufacturer to perform cleaning validation. Rather, as the title suggests, it presents “points to consider” as one designs a cleaning validation program for process equipment based on an understanding of one’s manufacturing and cleaning processes. In cleaning validation, there are generally *multiple* ways to accomplish the